First Patient Receives Antibody-based Prostate Cancer Treatment TLX591 for mCRPC

[Maxone73]

“previous data from a phase 2 trial evaluating TLX591 reflected 42.3 months for overall survival”

curetoday.com/view/first-pa...

[PCaWarrior]

More info: prnewswire.com/news-release...

3 registered trials: clinicals clinicaltrials.gov/search?c...

At least one of the trials does not exclude HSPC: "A Single Arm, Phase 2 Trial of External Beam Radiation Therapy (EBRT) in Combination With 177Lu-DOTA-TLX591-CHO in Patients With Biochemically Recurrent Oligometastatic, Prostate Specific Membrane Antigen-Expressing Prostate Cancer"

You need BCR, previous RP, chemo naive, oligometastatic, and a non-castrate T level.

TLX591 is a beta emitter. TLX592 is alpha. TLX592 is a derivative of J591 designed to have faster blood clearance. Alpha might improve results. There are side effects that need to be worked out.

TLX592 trial: clinicaltrials.gov/study/NC...

Sartor and my MO are hopeful about alpha therapies.

[Maxone73 in reply to PCaWarrior]

thanks!